Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Aug;28(3):503-523.
doi: 10.1016/j.cld.2024.03.011. Epub 2024 May 22.

Renal Complications in Portal Hypertension

Adrià Juanola  1 , Ann Thu Ma  2 , Jordi Gratacós-Ginès  1 , Anna Soria  1 , Cristina Solé  3 , Elisa Pose  1 , Pere Ginès  4
Affiliations
Review

Renal Complications in Portal Hypertension

Adrià Juanola et al. Clin Liver Dis. 2024 Aug.

Abstract

Acute kidney injury (AKI) is a common complication among patients with decompensated cirrhosis and its development is associated with worse prognosis in terms of survival. Patients with decompensated cirrhosis may develop a unique type of AKI, known as hepatorenal syndrome (HRS-AKI), characterized by marked impairment of kidney function due to haemodynamic changes that occur in late stages of liver cirrhosis. Besides, patients with cirrhosis also may develop chronic alterations of kidney function (chronic kidney disease, CKD), the incidence of which is increasing markedly and may be associated with clinical complications. The aim of this review is to provide the reader with an update of the most relevant aspects of alterations of kidney function in patients with cirrhossi that may be useful for theri clinical practice.

Keywords: Acute kidney injury; Biomarkers; Chronic kidney disease; Cirrhosis; HRS-AKI; Liver transplantation; Terlipressin.

PubMed Disclaimer

Conflict of interest statement

Disclosure P. Ginès has received research funding from Gilead, United States, Mallinckrodt, Grifols, Spain, Ferring, Switzerland and has consulted or attended advisory boards for Grifols SA, Ferring Pharmaceuticals, Gilead, Intercept, Martin Pharmaceuticals, Promethera, Sequana, RallyBio, Behring, Ocelot Bio, SeaBe Life, Merck, Sharp and Dohme, and Boehringer-Ingelheim. Authors’ contributions: A. Juanola, A.T. Ma, J. Gratacós-Ginès, A. Soria, C. Solé, E. Pose and P. Ginès: review and interpretation of data, drafting of the manuscript, and critical revision of the manuscript.

MeSH terms